This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Although several drugs are effective in treating the insulin resistance associated with Type 2 diabetes mellitus, the dietary supplement chromium picolinate has particular advantages for patients with HIV-disease. This dietary supplement has been shown to improve insulin sensitivity in patients with Type 2 diabetes mellitus. This pilot project will investigate the effect of 1000 ug of chromium as chromium picolinate on the insulin resistance of HIV disease. Chromium supplements will be given daily over a 4 month course of treatment and the insulin sensitivity will be determined at baseline and after 2 and 4 months of therapy. Possible toxicity will be monitored every 2 weeks. This pilot data will be used as preliminary data for a larger study on the mechanism by which chromium improves insulin sensitivity.
Showing the most recent 10 out of 283 publications
